Claritev (NYSE:CTEV) SVP William Mintz Sells 8,431 Shares

Claritev (NYSE:CTEV) SVP William Mintz sold 8,431 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $34.24, for a total value of $288,677.44. Following the completion of the transaction, the senior vice president directly owned 71,195 shares in the company, valued at approximately $2,437,716.80. This trade represents a 10.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Claritev Stock Up 0.3%

Shares of NYSE CTEV opened at $35.06 on Thursday. The business has a fifty day simple moving average of $29.32 and a two-hundred day simple moving average of $23.86. The firm has a market cap of $597.77 million, a PE ratio of -2.06 and a beta of 0.74. Claritev has a twelve month low of $11.50 and a twelve month high of $74.07.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Claritev from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Canaccord Genuity Group boosted their price target on shares of Claritev from $37.00 to $43.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a research report on Wednesday, June 24th. Citigroup reiterated a “buy” rating and set a $45.00 price objective (up from $40.00) on shares of Claritev in a research note on Monday. Finally, Barclays assumed coverage on shares of Claritev in a report on Friday, April 24th. They set an “overweight” rating and a $28.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $42.83.

Institutional Trading of Claritev

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. acquired a new stake in shares of Claritev in the 3rd quarter worth $1,245,000. Vanguard Group Inc. acquired a new position in Claritev during the 3rd quarter valued at about $27,483,000. Ameritas Investment Partners Inc. acquired a new position in Claritev during the 3rd quarter valued at about $42,000. Russell Investments Group Ltd. purchased a new stake in Claritev in the third quarter valued at about $369,000. Finally, Legal & General Group Plc purchased a new stake in Claritev in the third quarter valued at about $45,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.